natgillin/translations-raw huggingface dataset:
In repeated dose toxicity studies in cynomolgus monkeys, no definitive conclusions could be drawn on the adverse effect on male reproductive organs. 
Iz študij toksičnosti pri ponavljajočih odmerkih pri opicah cynomolgus dokončni zaključki o neželenih učinkih na moške reproduktivne organe niso mogoči.
Swollen ankles or other body parts due to your body retaining too much water Not being able to sleep 
• oteklost gležnjev ali drugih delov telesa zaradi čezmernega zadrževanja vode v telesu
The efficacy results are presented in Table 4. 
Rezultati o učinkovitosti so prikazani v preglednici 4.
If you have ever had a chemotherapy medicine from the class called anthracyclines, e.g. doxorubicin or epirubicin - these medicines can damage heart muscle and increase the risk of heart problems with Perjeta. 
• če ste predhodno prejemali kemoterapevtike iz skupine, imenovane antraciklini - npr. doksorubicin ali epirubicin - to so zdravila, ki lahko poškodujejo srčno mišico in povečajo tveganje za nastanek težav s srcem ob zdravljenju z zdravilom Perjeta.
Only chemotherapy-naive patients were treated and they received low cumulative doses of epirubicin (up to 300 mg/m2). 
Zdravljenje so prejemali le bolniki, ki se predhodno še niso zdravili s kemoterapijo, in prejeli so majhne kumulativne odmerke epirubicina (do 300 mg/m2).
Patients with metastases, bilateral breast cancer, clinically important cardiac risk factors (see section 4.4) or LVEF < 55% were not included. 
Bolnice z metastazami, bilateralnim rakom dojk, klinično pomembnimi dejavniki tveganja za srčno bolezen (glejte poglavje 4.4) ali LVEF < 55 % niso bile vključene.
Perjeta and trastuzumab should be withheld for at least 3 weeks for any signs and symptoms suggestive of congestive heart failure. 
Zdravljenje z zdravilom Perjeta in trastuzumabom je treba prekiniti za vsaj 3 tedne v primeru znakov in simptomov, ki kažejo na kongestivno srčno popuščanje.
What Perjeta is and what it is used for What you need to know before you are given Perjeta How you are given Perjeta Possible side effects 
Kaj je zdravilo Perjeta in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Perjeta Kako boste prejeli zdravilo Perjeta
Sequential use of Perjeta (in combination with trastuzumab and a taxane) has been evaluated following the epirubicin or doxorubicin component of many anthracycline-based regimens in the APHINITY and BERENICE studies. 
Zaporedno uporabo zdravila Perjeta (v kombinaciji s trastuzumabom in taksanom) po epirubicinski ali doksorubicinski komponenti številnih shem na osnovi antraciklina so ocenili v študijah APHINITY in
There were too few patients with inflammatory breast cancer to draw any firm conclusions. 
Bolnic z vnetnim rakom dojk je bilo premalo za trdne zaključke.
Patients should have a pre-treatment left ventricular ejection fraction (LVEF) of ≥ 50%. 
Bolniki morajo imeti iztisni delež levega prekata (LVEF) pred zdravljenjem ≥ 50 %.
The efficacy results from the CLEOPATRA study are summarised in Table 3. 
Rezultati učinkovitosti študije CLEOPATRA so povzeti v preglednici 3.
† Evaluated in patients with Best Overall Response of CR or PR. ^ Objective response rate and duration of response are based on IRF-assessed tumour assessments. 
† Ocenjeno pri bolnikih z najboljšim celokupnim odgovorom CR ali PR. ^ Delež objektivnega odgovora in trajanje odgovora temeljita na oceni tumorja po IRF.
Approximately half the patients in each treatment group had hormone receptor-positive disease (defined as oestrogen receptor (ER) positive and/or progesterone receptor (PgR) positive) and approximately half of the patients in each treatment group had received prior adjuvant or neoadjuvant therapy. 
Približno polovica bolnikov v vsaki od obeh terapevtskih skupin je imela hormonsko odvisen karcinom (opredeljen s pozitivnimi estrogenskimi receptorji (ER) in/ali progesteronskimi receptorji (PR)) in približno polovica bolnikov v vsaki od obeh terapevtskih skupin je predhodno prejemala adjuvantno ali neoadjuvantno zdravljenje.
In addition, consistent with foetal growth restrictions, secondary to oligohydramnios, lung hypoplasia (1 of 6 in 30 mg/kg and 1 of 2 in100 mg/kg groups), ventricular septal defects (1 of 6 in 30 mg/kg group), thin ventricular wall (1 of 2 in 100 mg/kg group) and minor skeletal defects (external - 3 of 6 in 30 mg/kg group) were also noted. 
Dodatno so skladno z motnjami v rasti zarodka, sekundarno oligohidramniju, opazili tudi pljučno hipoplazijo (1 od 6 pri skupini z 30 mg/kg in 1 od 2 pri skupini z 100 mg/kg), okvaro ventrikularnega septuma (1 od 6 pri skupini z 30 mg/kg), tanko steno prekata (1 od 2 pri skupini z 100 mg/kg) in manjše skeletne okvare (eksterne 3 od 6 pri 30 mg/kg).
Patients were treated with Perjeta and trastuzumab until disease progression, withdrawal of consent or unmanageable toxicity. 
Bolniki so zdravilo Perjeta in trastuzumab prejemali do napredovanja bolezni, umika soglasja ali pojava neobvladljivih toksičnih učinkov.
When the diarrhoea is under control treatment with pertuzumab may be reinstated. 
Ko je driska uravnana, lahko zdravljenje s pertuzumabom ponovno uvedemo.
In the adjuvant setting, Perjeta should be administered in combination with trastuzumab for a total of one year (up to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first) as part of a complete regimen for early breast cancer and regardless of the timing of surgery. 
V okviru adjuvantnega zdravljenja je treba zdravilo Perjeta uporabljati v kombinaciji s trastuzumabom v skupnem trajanju eno leto (do 18 ciklov ali do ponovitve bolezni ali neobvladljivih toksičnih učinkov, kar od tega se pojavi prej), ki predstavlja del celostnega zdravljenja zgodnjega raka dojk in ne glede na čas operacije.
For recommendations on delayed or missed doses, please refer to Table 1 below. 
Zamujeni ali izpuščeni odmerki Za priporočila glede zamujenih ali izpuščenih odmerkov glejte spodnjo preglednico 1.
Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of LVEF declines. 
Bolniki, predhodno zdravljeni z antraciklini ali obsevanjem v predelu prsnega koša, imajo lahko večje tveganje za zmanjšanje LVEF.
95% CI for one sample binomial using Pearson-Clopper method. 
1 95-% interval zaupanja za binomsko porazdelitev z enim vzorcem po Pearson-Clopperjevi metodi.
You will be given 420 mg of Perjeta over 30 to 60 minutes. 
• Dobili boste 420 mg zdravila Perjeta v 30 do 60 minutah.
The CHMP recommends that the terms of the marketing authorisation(s) should be varied. 
Odbor CHMP zato priporoča spremembo pogojev dovoljenja za promet z zdravilom.
Tumour lysis syndrome (a condition which may happen when cancer cells die quickly, causing changes in blood levels of minerals and metabolites shown in a blood test). 
• sindrom razpada tumorja (stanje, ki se lahko pojavi, ko rakave celice hitro propadejo; to povzroči spremembe vrednosti mineralov in presnovkov v krvi, kar pokaže preiskava krvi).
Patients were then randomised to receive Perjeta or placebo, in combination with adjuvant trastuzumab and chemotherapy. 
Bolnike so nato randomizirali na prejemanje zdravila Perjeta ali placeba v kombinaciji s trastuzumabom, danim adjuvantno, in kemoterapijo.
Patients in the pivotal trial CLEOPATRA were tested at multiple time-points for anti-drug antibodies (ADA) to Perjeta. 
Bolnikom v ključnem preskušanju CLEOPATRA so ob različnih časih večkrat določali protitelesa proti zdravilu (ADA - anti-drug antibodies) Perjeta.
Treatment with Perjeta and trastuzumab may continue until disease progression or unmanageable toxicity even if treatment with docetaxel is discontinued. 
Zdravljenje z zdravilom Perjeta in trastuzumabom se lahko nadaljuje do napredovanja bolezni ali pojava neobvladljivih toksičnih učinkov tudi v primeru ukinitve zdravljenja z docetakselom.
Symptoms may include kidney problems (weakness, shortness of breath, fatigue and confusion), heart problems (fluttering of the heart of a faster or slower heartbeat), seizures, vomiting or diarrhoea and tingling in the mouth, hands or feet 
Simptomi lahko vključujejo težave z ledvicami (oslabelost, kratko sapo, utrujenost in zmedenost), težave s srcem (trepetanje srca s hitrejšim ali počasnejšim bitjem), krče, bruhanje ali drisko in mravljinčenje v ustih, dlaneh ali stopalih.
Patients with clinically important cardiac risk factors were not included (see section 4.4). 
Bolniki s klinično pomembnimi tveganji za razvoj srčnega obolenja niso bili vključeni (glejte poglavje 4.4).
No specific fertility studies in animals have been performed to evaluate the effect of pertuzumab. 
Pri živalih niso izvedli specifičnih študij za oceno vpliva pertuzumaba na plodnost.
In case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted. 
Pri prevelikem odmerjanju je treba skrbno nadzorovati bolnikove znake in simptome neželenih učinkov in uvesti ustrezno simptomatsko zdravljenje.
Tell a doctor or nurse straight away, if you notice any of the side effects above. 
Zdravniku ali medicinski sestri morate takoj povedati, če opazite katerega od zgoraj naštetih neželenih učinkov.
Perjeta and trastuzumab were given at standard doses in a 3-weekly regimen. 
Zdravilo Perjeta in trastuzumab so dajali v standardnih odmerkih po 3-tedenski shemi.
• CLEOPATRA, in which Perjeta was given in combination with docetaxel and trastuzumab to patients with metastatic breast cancer (n=453) 
• CLEOPATRA, v katerem so zdravilo Perjeta dajali v kombinaciji z docetakselom in trastuzumabom bolnikom z metastatskim rakom dojk (n = 453);
Intravenous administration of pertuzumab from GD19 through GD50 (period of organogenesis) was embryotoxic, with dose-dependent increases in embryo-foetal death between GD25 to GD70. 
Intravenska uporaba pertuzumaba od 19. do 50. gestacijskega dne (GD, obdobje organogeneze) je bila embriotoksična; embriofetalne smrti so se povečevale od odmerka odvisno od GD 25 do GD 70.
Patients' median LVEF at baseline was 65.0% (range 50% - 88%) in both groups. 
Mediana LVEF bolnikov pred začetkom zdravljenja je bila 65 (razpon 50−88 % v obeh skupinah).
Alternatively, docetaxel can be given at 100 mg/m2 on a 3 weekly schedule from the start, again depending on the chosen regimen. 
Druga možnost je odmerek docetaksela 100 mg/m2 po 3-tednskem razporedu že od začetka, ponovno glede na izbrano shemo.
You will be given 840 mg of Perjeta over 60 minutes. 
• Dobili boste 840 mg zdravila Perjeta v 60 minutah.
Consistent results were observed across pre-specified patient subgroups including the subgroups based on stratification factors of geographic region and prior adjuvant/neoadjuvant therapy or de novo metastatic breast cancer (see Figure 1). 
Ugotovili so skladnost rezultatov po vnaprej opredeljenih podskupinah bolnikov, vključno s podskupinami glede na stratifikacijske dejavnike: geografsko območje, predhodno adjuvantno/neoadjuvantno zdravljenje ali de novo metastatski rak dojk (glejte sliko 1).
In the remaining 7 cases the events reported were indeed suggestive of IRR/ hypersensitivity/ anaphylaxis and in 3/7 of them, a causal relationship between the administration of pertuzumab and the fatal event could not be excluded. 
V preostalih 7 primerih so poročani dogodki nakazovali na infuzijsko reakcijo/preobčutljivost/anafilaksijo, v 3/7 primerov pa vzročne povezanosti med dajanjem pertuzumaba in smrtnim dogodkom ni bilo mogoče izključiti.
While pertuzumab alone inhibited the proliferation of human tumour cells, the combination of pertuzumab and trastuzumab significantly augmented antitumour activity in HER2-overexpressing xenograft models. 
Sam pertuzumab je sicer zavrl razmnoževanje humanih tumorskih celic, toda kombinacija pertuzumaba s trastuzumabom je bistveno povečala protitumorsko delovanje v ksenotransplantatnih modelih s čezmerno izraženim HER2.
Treatment Perjeta+Trastuzumab+Docetaxel and Perjeta+Trastuzumab are compared to Trastuzumab+ Docetaxel while Perjeta+Docetaxel is compared to Perjeta+Trastuzumab+Docetaxel. 
Zdravljenji Perjeta + trastuzumab + docetaksel in Perjeta + trastuzumab sta primerjani s trastuzumab + docetaksel, medtem ko je zdravljenje Perjeta + docetaksel primerjano s Perjeta + trastuzumab + docetaksel.
An infusion reaction was defined in the pivotal trials as any event reported as hypersensitivity, anaphylactic reaction, acute infusion reaction or cytokine release syndrome occurring during an infusion or on the same day as the infusion. 
Infuzijske reakcije Infuzijska reakcija je bila v ključnih preskušanjih opredeljena kot vsak dogodek, poročan kot preobčutljivost, anafilaktična reakcija, akutna infuzijska reakcija ali sindrom sproščanja citokinov, ki se je pojavil med infuzijo ali na dan infuzije.
Data available for Infusion Related Reactions (IRR) and anaphylaxis/hypersensitivity with fatal outcome for patients treated with Perjeta in clinical trials, data from published literature, and relevant data from the Roche global safety database showed that there were no cases of confirmed IRRs or anaphylaxis/hypersensitivity with a fatal outcome in pivotal clinical trials in patients treated with pertuzumab. 
Razpoložljivi podatki za infuzijske reakcije in anafilakso/preobčutljivost s smrtnim izidom za bolnike, zdravljene z zdravilom Perjeta v kliničnih preskušanjih, podatki iz objavljene literature in ustrezni podatki iz globalne podatkovne zbirke o varnosti podjetja Roche so pokazali, da v ključnih kliničnih preskušanjih pri bolnikih, zdravljenih s pertuzumabom, ni bilo potrjenih primerov infuzijskih reakcij ali anafilaksije/preobčutljivosti s smrtnim izidom.
Loss of or altered taste 
• izguba okusa ali spremenjen okus • zvišana telesna temperatura
After dilution, one ml of solution contains approximately 3.02 mg of pertuzumab for the initial dose and approximately 1.59 mg of pertuzumab for the maintenance dose (see section 6.6). 
Po razredčitvi vsebuje en ml raztopine približno 3,02 mg pertuzumaba v začetnem odmerku in približno 1,59 mg pertuzumaba v vzdrževalnem odmerku (glejte poglavje 6.6).
After dilution, one ml of solution should contain approximately 3.02 mg of pertuzumab (840 mg/278 ml) for the initial dose where two vials are required and approximately 1.59 mg of pertuzumab (420 mg/264 ml) for the maintenance dose where one vial is required. 
Po razredčitvi mora en ml raztopine vsebovati približno 3,02 mg pertuzumaba (840 mg/278 ml) za začetni odmerek, za katerega sta potrebni dve viali, in približno 1,59 mg (420 mg/264 ml) pertuzumaba za vzdrževalni odmerek, za katerega je potrebna ena viala.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsquent updates published on the European medicines web-portal. 
• Redno posodobljena poročila o varnosti zdravila (PSUR) Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
Overall 6% of patients had inflammatory breast cancer, 25% had locally advanced breast cancer and 69% had operable breast cancer. 
Skupno je imelo 6 % bolnic vnetni rak dojk, 25 % lokalno napredovali rak dojk in 69 % operabilni rak dojk.
If you are given Perjeta with trastuzumab and chemotherapy at the same time, some side effects may also be due to these other medicines. 
Če hkrati z zdravilom Perjeta prejemate trastuzumab in kemoterapijo, so nekateri neželeni učinki lahko tudi posledica teh zdravil.
Perjeta has not been studied in patients with: a pre-treatment LVEF value of < 50%; a prior history of congestive heart failure (CHF); LVEF declines to < 50% during prior trastuzumab adjuvant therapy; or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m2 of doxorubicin or its equivalent. 
Zdravila Perjeta niso proučevali pri bolnikih: z vrednostjo LVEF pred zdravljenjem < 50 %; z anamnezo kongestivnega srčnega popuščanja; s padcem LVEF na < 50 % med predhodnim adjuvantnim zdravljenjem s trastuzumabom; s stanji, ki bi lahko okvarila delovanje levega prekata, kot so npr. neurejena hipertenzija, nedavni miokardni infarkt, resne motnje srčnega ritma, ki so zahtevale zdravljenje, predhodna kumulativna izpostavljenost antraciklinu do > 360 mg/m2 doksorubicina ali njegovega ekvivalenta.
In both studies most events were mild to moderate in severity. 
obeh preskušanjih je bila po resnosti večina dogodkov blagih do zmernih.
Overall 7% of patients had inflammatory breast cancer, 32% had locally advanced breast cancer and 61% had operable breast cancer. 
Skupno je imelo 7 % bolnic vnetni rak dojk, 32 % lokalno napredovali rak dojk in 61 % operabilni rak dojk.
However, in the group treated with Perjeta in combination with TCH, docetaxel was given intravenously at 75 mg/m2 (no escalation was permitted) and carboplatin (AUC 6) was given intravenously every three weeks. 
V skupini, zdravljeni z zdravilom Perjeta v kombinaciji s shemo TCH, pa so docetaksel dali intravensko v odmerku 75 mg/m2 (povečanje ni bilo dovoljeno) in karboplatin (AUC 6) intravensko vsake tri tedne.
With doses of 15 mg/kg and higher, intermittent mild treatment-associated diarrhoea was noted. 
Ob odmerkih 15 mg/kg in več so ugotovili intermitentno, blago z zdravilom povezano drisko.
Ask your doctor about whether you can breast-feed during or after treatment with Perjeta. 
• Z zdravnikom se posvetujte, ali smete med zdravljenjem z zdravilom Perjeta ali po njem dojiti.
Based on the results of the population pharmacokinetic analysis, pertuzumab exposure in patients with mild (creatinine clearance [CLcr] 60 to 90 ml/min, N=200) and moderate renal impairment (CLcr 30 to 60 ml/min, N=71) was similar to that in patients with normal renal function (CLcr greater than 90 ml/min, N=200). 
Na osnovi rezultatov farmakokinetične populacijske analize je bila izpostavljenost pertuzumabu pri bolnikih z blago okvaro ledvic (očistek kreatinina [Clcr] = 60 do 90 ml/min, n = 200) ter bolnikih z zmerno okvaro ledvic (Clcr = 30 do 60 ml/min, n = 71) podobna kot pri bolnikih z normalno funkcijo ledvic(Clcr večji kot
HR= hazard ratio; CI= confidence interval; Pla= placebo; Ptz= pertuzumab (Perjeta); T= trastuzumab (Herceptin); D= docetaxel. 
HR = razmerje ogroženosti; Pla = placebo; Ptz = pertuzumab (zdravilo Perjeta); T = trastuzumab (zdravilo Herceptin); D = docetaksel
• NEOSPHERE (n=309) and TRYPHAENA (n=218), in which neoadjuvant Perjeta was given in combination with trastuzumab and chemotherapy to patients with locally advanced, inflammatory, or early breast cancer 
• NEOSPHERE (n = 309) in TRYPHAENA (n = 218), kjer so zdravilo Perjeta dajali kot neoadjuvantno zdravljenje v kombinaciji s trastuzumabom in kemoterapijo bolnicam z lokalno napredovalim, vnetnim ali zgodnjim rakom dojk;
Based on the population pharmacokinetic analysis, no significant difference was observed in the pharmacokinetics of pertuzumab between patients < 65 years (n=306) and patients ≥ 65 years (n=175). 
Na osnovi populacijske farmakokinetične analize niso ugotovili pomembnih farmakokinetičnih razlik za pertuzumab med bolniki, ki so bili mlajši od 65 let (n = 306), in bolniki, ki so bili stari 65 let ali več (n = 175).
It is given by a drip into a vein (intravenous infusion) once every three weeks. 
• Dobili ga boste v obliki infuzije v žilo (intravenske infuzije) vsake 3 tedne.
The pCR rates were lower in the subgroup of patients with hormone receptor positive tumours (range 46.2% to 50.0%) than in patients with hormone receptor-negative tumours (range 65.0% to 83.8%). 
Deleži pCR so bili nižji v podskupini bolnic s hormonsko odvisnimi tumorji (razpon 46,2 % do 50,0 %) v primerjavi z bolnicami s hormonsko neodvisnimi tumorji (razpon vrednosti 65,0 % do 83,8 %).
On the first day when only Perjeta was administered, the overall frequency of infusion reactions was 9.8% in the placebo-treated group and 13.2% in the Perjeta-treated group, with the majority of infusion reactions being mild or moderate. 
Prvi dan, ko je bilo uporabljeno le zdravilo Perjeta, je bila celotna pogostnost infuzijskih reakcij v skupini, ki je prejemala placebo, 9,8 %, in v skupini, ki je prejemala zdravilo Perjeta, 13,2 %; večina teh reakcij je bila blagih ali zmernih.
As Perjeta was used with trastuzumab and chemotherapy in these trials, it is difficult to ascertain the causal relationship of an adverse event to a particular medicinal product. 
Ker so v teh preskušanjih zdravilo Perjeta uporabljali skupaj s trastuzumabom in kemoterapijo, je težko ugotoviti vzročno povezanost neželenega učinka s posameznim zdravilom.
The difference in pCR rate is considered likely to translate into a clinically meaningful difference in long term outcomes and is supported by positive trends in PFS (HR 0.69, 95% CI 0.34, 1.40) and DFS (HR 0.60, 95% CI 0.28, 1.27). 
Razlika v deležu pCR se bo verjetno odrazila v klinično pomembno razliko v dolgoročnih izidih; podprta je s pozitivnimi trendi v PFS (razmerje ogroženosti 0,69, 95-% interval zaupanja 0,34; 1,40) in DFS (razmerje ogroženosti 0,60, 95-% interval zaupanja 0,28; 1,27).
Following surgery all patients received 3 cycles of 5fluorouracil (600 mg/m2), epirubicin (90 mg/m2), cyclophosphamide (600 mg/m2) (FEC) given intravenously every three weeks, and trastuzumab administered intravenously every three weeks to complete one year of therapy. 
Po operaciji so vse bolnice prejele 3 cikle kombinacije 5-fluorouracila (600 mg/m2), epirubicina (90 mg/m2) in ciklofosfamida (600 mg/m2) (FEC) intravensko vsake tri tedne in trastuzumab intravensko vsake tri tedne do zaključka enoletnega zdravljenja.
Therefore, there is no need to adjust the dosage of pertuzumab based on these covariates. 
Zato odmerka pertuzumaba ni treba prilagajati glede na ti sospremenljivki.
Figure 1 IRF-assessed PFS by patient subgroup 
IRF-ova ocena preživetja brez napredovanja bolezni po podskupinah bolnikov
When administered with Perjeta in the adjuvant setting, the recommended dose of paclitaxel is 80 mg/m2 once weekly for 12 weekly cycles. 
Priporočeni odmerek paklitaksela ob zdravilu Perjeta v adjuvantnem zdravljenju je 80 mg/m2 enkrat na teden v 12-tedenskih ciklih.
If you forget to have Perjeta 
Če ste pozabili na zdravilo Perjeta
Patients considered suitable for neoadjuvant treatment with trastuzumab plus anthracycline/taxane-based chemotherapy were allocated to receive one of the two following regimens prior to surgery as follows: 
Bolnike, za katere so menili, da so primerni za neoadjuvantno zdravljenje s trastuzumabom in kemoterapijo na osnovi antraciklinov/taksanov, so pred operacijo dodelili na prejemanje ene od naslednjih dveh spodaj navedenih shem:
In conclusion, administration of Pertuzumab may cause Infusion Related Reactions (IRR) and hypersensitivity/anaphylaxis reactions that can be associated with fatal outcome and the Product Information should be updated to reflect such outcome. 
Zaključili so, da dajanje pertuzumaba lahko povzroči infuzijske reakcije in reakcije preobčutljivosti/anafilaksije, ki so lahko povezane s smrtnim izidom, informacije o zdravilu pa je treba posodobiti, da bo iz njih to razvidno.
• the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence (see section 5.1) 
• adjuvantno zdravljenje odraslih bolnikov z zgodnjim rakom dojk z visokim tveganjem za ponovitev (glejte poglavje 5.1).
However sensitivity analyses performed at the recommended dose and schedule of Perjeta showed that at the extreme values of these two covariates, there was no significant impact on the ability to achieve target steady-state concentrations identified in preclinical tumour xenograft models. 
Toda v analizah občutljivosti ob priporočenem odmerjanju in razporedu uporabe zdravila Perjeta ti sospremenljivki niti pri svojih skrajnih vrednostih nista pomembno vplivali na sposobnost za doseganje ciljnih koncentracij v stanju dinamičnega ravnovesja, ugotovljenih v predkliničnih ksenotransplantacijskih tumorskih modelih.